J&J Ultracet Could Clear FDA In May; Ultram Exclusivity Runs To 2003
Executive Summary
J&J hopes to receive approval for Ultracet for use in acute pain during May.
You may also be interested in...
J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram
Johnson & Johnson's Ultracet delivers a faster onset of action than Ultram (tramadol) alone, labeling for the combination tramadol/acetaminophen drug notes.
J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram
Johnson & Johnson's Ultracet delivers a faster onset of action than Ultram (tramadol) alone, labeling for the combination tramadol/acetaminophen drug notes.
J&J Ultracet Approval Decision Expected By December, Label Talks Underway
Johnson & Johnson expects FDA will make an approval decision on its analgesic Ultracet within two to three months, the company told analysts July 17.